These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 6797851)

  • 1. A comparison of cobra venom factor-induced depletion of serum C3 in eight different strains of mice.
    Finnie JA; Stewart RB; Aston WP
    Dev Comp Immunol; 1981; 5(4):697-701. PubMed ID: 6797851
    [No Abstract]   [Full Text] [Related]  

  • 2. Complement and myoblast transfer therapy: donor myoblast survival is enhanced following depletion of host complement C3 using cobra venom factor, but not in the absence of C5.
    Hodgetts SI; Grounds MD
    Immunol Cell Biol; 2001 Jun; 79(3):231-9. PubMed ID: 11380675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphism of murine C3 controlled by a single co-dominant locus on chromosome 17.
    Natsuume-Sakai S; Hayakawa JI; Takahashi M
    J Immunol; 1978 Aug; 121(2):491-8. PubMed ID: 681746
    [No Abstract]   [Full Text] [Related]  

  • 4. The location of the C3 and GLO (glyoxalase 1) loci of the IXth linkage group in mice.
    Rubinstein P; Vienne K; Hoecker GF
    J Immunol; 1979 Jun; 122(6):2584-9. PubMed ID: 448134
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of decomplementation on the infectious course of Sendai virus in mice.
    Finnie JC; Aston WP; O'Shaughnessy MV; Stewart RB
    Can J Microbiol; 1982 May; 28(5):474-7. PubMed ID: 6286080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of cobra venom factor on the response of Wistar-Furth rats to the Gross-virus-induced (C58NT)D lymphoma.
    Mizoguchi Y; Osler AG
    Int Arch Allergy Appl Immunol; 1979; 58(3):302-12. PubMed ID: 422287
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombocytopenia induced in mice by thromboplastin infusion--essential role of the third complement component.
    Giraudo LA; Dalmasso AP
    Thromb Haemost; 1978 Jun; 39(3):733-42. PubMed ID: 705702
    [No Abstract]   [Full Text] [Related]  

  • 8. The role of complement in cigarette smoke-induced chemotactic activity of lung fluids.
    Kew RR; Ghebrehiwet B; Janoff A
    Am Rev Respir Dis; 1986 Mar; 133(3):478-81. PubMed ID: 3954255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Functional assay of C5-activating and nonactivating cobra venom factor preparations in the mouse system.
    Van den Berg CW; Aerts PC; Van Dijk H
    J Immunol Methods; 1990 Oct; 133(2):199-206. PubMed ID: 2230138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substances that can trigger activation of the alternative pathway of complement have anti-melanoma activity in mice.
    Cooper PD; Sim RB
    Int J Cancer; 1984 May; 33(5):683-7. PubMed ID: 6724743
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Generation and characterization of transgenic mice expressing cobra venom factor.
    Andrä J; Halter R; Kock MA; Niemann H; Vogel CW; Paul D
    Mol Immunol; 2002 Oct; 39(5-6):357-65. PubMed ID: 12220893
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged complement activation in mice.
    Simpson IJ; Moran J; Evans DJ; Peters DK
    Kidney Int; 1978 Jun; 13(6):467-71. PubMed ID: 713282
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of cobra venom factor on alternative pathway hemolytic activity in mice.
    Joiner KA; Hawiger A; Gelfand JA
    Immunol Commun; 1980; 9(3):277-81. PubMed ID: 7399569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of complement activation in tumour necrosis factor-induced lethal hepatitis.
    Libert C; Wielockx B; Grijalba B; Van Molle W; Kremmer E; Colten HR; Fiers W; Brouckaert P
    Cytokine; 1999 Aug; 11(8):617-25. PubMed ID: 10433810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo anti-complementary activities of the cobra venom factors from Naja naja and Naja haje.
    Van den Berg CW; Aerts PC; Van Dijk H
    J Immunol Methods; 1991 Feb; 136(2):287-94. PubMed ID: 1999656
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allotypes of C3 in laboratory and wild mouse distinguished by alloantisera.
    Natsuume-Sakai S; Moriwaki K; Amano S; Hayakawa J; Kaidoh T; Takahashi M
    J Immunol; 1979 Jul; 123(1):216-21. PubMed ID: 87473
    [No Abstract]   [Full Text] [Related]  

  • 17. Genetic control of MuLV-gs expression in crosses between high and low leukemia incidence strains.
    Hilgers J; Galesloot J
    Int J Cancer; 1973 May; 11(3):780-93. PubMed ID: 4364724
    [No Abstract]   [Full Text] [Related]  

  • 18. In vivo release of lymphokines in different strains of mice.
    Neta R; Salvin SB
    Cell Immunol; 1980 Apr; 51(1):173-8. PubMed ID: 6153932
    [No Abstract]   [Full Text] [Related]  

  • 19. The selective localization of B lymphocytes in the spleen and the role of complement receptors.
    Kraal G; Van Hoogstraten I; Klerx JP; Van Dijk H
    Eur J Immunol; 1985 Jul; 15(7):681-6. PubMed ID: 3874080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Classical and alternative pathway complement activation are not required for reactive systemic AA amyloid deposition in mice.
    Hutchinson WL; Herbert J; Botto M; Pepys MB
    Immunology; 2004 Jun; 112(2):250-4. PubMed ID: 15147568
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.